Global Pharmacogenomics Technology (Theranostics & CDx) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Pharmacogenomics Technology (Theranostics & CDx) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

According to our (Global Info Research) latest study, the global Pharmacogenomics Technology (Theranostics & CDx) market size was valued at US$ 11440 million in 2023 and is forecast to a readjusted size of USD 28980 million by 2030 with a CAGR of 14.4% during review period.

Pharmacogenomics Technology (Theranostics & CDx) manufacturers include Illumina, Roche and Agilent etc. The top 3 company holds a share of more than 50%. North America takes up the largest sales market, with a share of more than 40%, followed by Europe and China, with the share of about 30% and 10% respectively.

This report is a detailed and comprehensive analysis for global Pharmacogenomics Technology (Theranostics & CDx) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Pharmacogenomics Technology (Theranostics & CDx) market size and forecasts, in consumption value ($ Million), 2019-2030

Global Pharmacogenomics Technology (Theranostics & CDx) market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Pharmacogenomics Technology (Theranostics & CDx) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030

Global Pharmacogenomics Technology (Theranostics & CDx) market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Pharmacogenomics Technology (Theranostics & CDx)

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Pharmacogenomics Technology (Theranostics & CDx) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Illumina, Roche, Agilent, Abbott, Thermofisher, Qiagen, Guardant Health, MGI Tech Co., Ltd., Amoydx Biology, Genomics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Pharmacogenomics Technology (Theranostics & CDx) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Pharmacogenomics Technology (Theranostics & CDx) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Instrument
Reagents and Consumables
Others

Market segment by Application
Tumor
Diabetes
Mental Diseases
Cardiovascular Diseases
Others

Market segment by players, this report covers
Illumina
Roche
Agilent
Abbott
Thermofisher
Qiagen
Guardant Health
MGI Tech Co., Ltd.
Amoydx Biology
Genomics

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Pharmacogenomics Technology (Theranostics & CDx) product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Pharmacogenomics Technology (Theranostics & CDx), with revenue, gross margin, and global market share of Pharmacogenomics Technology (Theranostics & CDx) from 2019 to 2024.

Chapter 3, the Pharmacogenomics Technology (Theranostics & CDx) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Pharmacogenomics Technology (Theranostics & CDx) market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Pharmacogenomics Technology (Theranostics & CDx).

Chapter 13, to describe Pharmacogenomics Technology (Theranostics & CDx) research findings and conclusion.